Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?

Eli Lilly and Company (LLY) is a premier global pharmaceutical leader specializing in developing breakthrough therapies across neuroscience, oncology, immunology, and cardiometabolic health. Today, Lilly is at the forefront of a medical revolution, driven by its leadership in incretin-based medicines for Type 2 diabetes and obesity, such as Mounjaro and Zepbound. Beyond metabolic health, the company is advancing high-impact treatments for Alzheimer’s disease and cancer. Eli Lilly is now, with an agreement with Insilico Medicine, expanding that cutting-edge pharmaceutical portfolio into AI-designed drugs.

Headquartered in Indianapolis, Indiana, the company has a legacy spanning 150 years.

Fundamentals

See More
  • Market Capitalization, $K 837,704,896
  • Shares Outstanding, K 944,819
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 26,302 M
  • EBITDA $ 28,299 M
  • 60-Month Beta 0.40
  • Price/Sales 12.73
  • Price/Cash Flow 34.94
  • Price/Book 31.29

Options Overview Details

View History
  • Implied Volatility 43.70% (-2.95%)
  • Historical Volatility 32.80%
  • IV Percentile 85%
  • IV Rank 44.68%
  • IV High 64.53% on 04/07/25
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 2) 19.76 (2.15%)
  • Put/Call Vol Ratio 0.64
  • Today's Volume 27,007
  • Volume Avg (30-Day) 32,011
  • Put/Call OI Ratio 1.29
  • Today's Open Interest 300,548
  • Open Int (30-Day) 323,549
  • Expected Range 900.01 to 939.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $7.53
  • Number of Estimates 8
  • High Estimate $8.56
  • Low Estimate $6.61
  • Prior Year $3.34
  • Growth Rate Est. (year over year) +125.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
877.11 +4.86%
on 03/27/26
1,056.20 -12.92%
on 03/02/26
-132.22 (-12.57%)
since 02/27/26
3-Month
877.11 +4.86%
on 03/27/26
1,133.95 -18.89%
on 01/08/26
-157.98 (-14.66%)
since 12/26/25
52-Week
623.78 +47.45%
on 08/08/25
1,133.95 -18.89%
on 01/08/26
+97.26 (+11.82%)
since 03/28/25

Most Recent Stories

More News
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals...

CNTA : 39.72 (+44.02%)
LLY : 919.77 (+3.74%)
Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?

Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.

XLV : 146.61 (+1.94%)
LLY : 919.77 (+3.74%)
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disorders

CNTA : 39.72 (+44.02%)
LLY : 919.77 (+3.74%)
Futures Stronger to Begin Short Week

Futures tied to Canada's stock index moved higher on Monday, as commodity prices climbed amid a widening ...

LLY : 919.77 (+3.74%)
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity

Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study

LLY : 919.77 (+3.74%)
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years

LLY : 919.77 (+3.74%)
Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way

Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way

LLY : 919.77 (+3.74%)
Want Income and Growth? This Simple 3-ETF Portfolio Does Both

In today’s highly volatile market, this simple 3-ETF portfolio combines both steady income and long-term upside.

MO : 65.99 (-1.54%)
AAPL : 253.79 (+2.90%)
AVGO : 309.51 (+5.49%)
CVX : 206.90 (-1.81%)
VZ : 50.20 (-0.20%)
$SPX : 6,528.52 (+2.91%)
JPM : 294.16 (+3.66%)
JNJ : 244.44 (+0.80%)
SCHD : 30.68 (+0.66%)
ABBV : 217.49 (+2.05%)
BMY : 60.65 (+1.54%)
MSFT : 370.17 (+3.12%)
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1

LLY : 919.77 (+3.74%)
Members of Congress Bought These 5 Stocks—Should You?

Five stocks recently traded by members of Congress—from AI defense to GLP-1 leaders—could offer clues for investors building their watchlists

SMPL : 14.35 (-1.64%)
AVGO : 309.51 (+5.49%)
CBRL : 28.11 (+1.26%)
BBAI : 3.52 (+15.79%)
LLY : 919.77 (+3.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 963.90
2nd Resistance Point 944.02
1st Resistance Point 931.90
Last Price 919.77
1st Support Level 899.89
2nd Support Level 880.01
3rd Support Level 867.89

See More

52-Week High 1,133.95
Fibonacci 61.8% 939.07
Last Price 919.77
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.